Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | TNKS | O95271 | 4/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025074 | 0.84 | PARP1 (0.54) | PARP1TNKSTNKS2KDM4AKDM4B | |
| SCHEMBL3040436 | 0.84 | PARP1 (0.56) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL3035403 | 0.84 | KDM4A (0.41) | PARP1TNKSTNKS2KDM4AKDM4B | |
| SCHEMBL3039605 | 0.81 | EGLN1 (0.43) | PARP1TNKSTNKS2KDM4AKDM4B | |
| SCHEMBL1193169 | 0.80 | EGLN1 (0.55) | ADORA2AJAK2TYK2EGLN1NPC1 | |
| SCHEMBL3030437 | 0.77 | HTR3A (0.52) | PARP1TNKSTNKS2EGLN1NPC1 | |
| SCHEMBL3025607 | 0.75 | EGLN1 (0.73) | EGLN1 | |
| SCHEMBL13362757 | 0.75 | MGLL (0.47) | PARP1TNKSTNKS2NPC1 | |
| SCHEMBL3030884 | 0.75 | TUBB4A (0.48) | PARP1TNKSTNKS2EGLN1MAPK1 | |
| SCHEMBL3025673 | 0.75 | EGLN1 (0.43) | TNKSTNKS2EGLN1NPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | PARP1 637/4885TNKS 984/4885TNKS2 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.